{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019362","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.331615+00:00","generated_at":"2026-06-01T23:58:09.189952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric Biosciences reports Q1 net loss of $2.46M, advances EB-003, signs seven non-binding term sheets","bullets":["Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.","Seven non-binding term sheets with four partners could yield up to $410M milestones plus future royalties.","Lead asset EB-003 advancing toward IND filing and Phase 1 trial.","Raised $4.5M from warrant exercises in Q1.","Drug discovery platform generated >1,000 proprietary candidates across seven molecule classes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019362","json":"https://secwatch.observer/filing/0001493152-24-019362.json","markdown":"https://secwatch.observer/filing/0001493152-24-019362.md","text":"https://secwatch.observer/filing/0001493152-24-019362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224019362/0001493152-24-019362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224019362/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:58:09.189952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04119b787236c627c4186a6234dc5c0880f85b6c","claim":"Enveric Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income $2.46 million, EPS $0.61.","evidence_excerpt":"Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315224019362/0001493152-24-019362-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$2.46 million"},{"label":"EPS","value":"$0.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}